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COMMENTARY
TO THE EDITOR:
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Introduction
vonWillebrand disease (VWD) is a common bleeding disorder, which affects 1 in 100 individuals based
on laboratory testing and at least 1 in 1000 individuals based on presence of abnormal bleeding
symptoms.1,2 VWD was first described almost 100 years ago, and since the initial report, major
advances in both diagnostic testing and treatment options have improved outcomes for patients living
with VWD; however, many patients still experience significant complications and barriers to treatment.
An underlying problem is the lack of consistent unified definitions.
In recent work developing evidence-based guidelines for VWD,3,4 it was noted that studies on VWD
often used varying definitions. For example, studies of vonWillebrand factor (VWF) concentrates did not
have consistent definitions for major bleeding, studies on VWF prophylaxis did not use consistent
definitions of what constituted a prophylaxis regimen, and studies on desmopressin did not use
consistent definitions of desmopressin responsiveness. In addition, common bleeding conditions,
such as heavy menstrual bleeding (HMB) and postpartum hemorrhage are variably defined. Such
inconsistencies in describing study regimens and endpoints hinder the ability to compare study
outcomes and to advance treatment of patients with VWD.
We propose definitions for future use in VWD research to facilitate comparison of treatment options.
These definitions are based on the most common usage in the literature and endeavor to encompass the
most common situations in VWD. The proposed definitions were derived from existing literature and
discussed at the first in-person meetings of the guideline panels. Group members made amendments,
and the consensus document was circulated to the group. All authors approved the final document.
Desmopressin response
Proposed definition
Desmopressin response requires an increase of at least .2 times the baseline VWF activity level and
a sustained increase of both VWF and factor VIII (FVIII):C levels .0.50 IU/mL for at least 4 hours.
Submitted 29 October 2020; accepted 14 December 2020; published online 25
January 2021. DOI 10.1182/bloodadvances.2020003620.
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Comment
Desmopressin is typically given either subcutaneously, IV, or
intranasally. Response may be measured following any mode of
administration, but in some instances (eg, children), intranasal ad-
ministration may be suboptimal, and lack of measured response
may be due to poor administration rather than true lack of
response.
It is important to note that for some procedures, VWF activity levels
of.0.50 IU/mL but,1.00 IU/mL may be insufficient. Neurosurgery
or procedures with a very high bleeding risk may require levels of
at least 1.00 IU/mL, and therefore, a patient may be “desmo-
pressin responsive” but require VWF concentrate to achieve an
adequate level for surgical hemostasis. Similarly, VWF concen-
trate may be required to maintain levels for a prolonged period due
to tachyphylaxis.
Previous literature has used multiple definitions. Multiple sources
used a similar definition with complete response when levels were
at least 0.50 IU/mL.5-8 Others used a definition of at least 3 times
baseline increase and levels at least 0.30 IU/mL9 or 0.40 IU/mL.10
The authors feel it is most logical to use a specific cutoff that made
physiologic sense; therefore, an increase of VWF into the normal
range of .0.5 IU/mL is considered optimal. There is evidence that
patients with VWF levels ,0.50 IU/mL may experience bleeding11;
therefore, a cutoff of 0.50 IU/mL is suggested. Prolonged increased
VWF and FVIII levels are associated with risk of thrombosis12,13;
therefore, the goal is to achieve optimal hemostasis while limiting
the amount of time patients are exposed to excess VWF and FVIII.
Some patients may experience minor bleeding episodes that
clinically respond to desmopressin (eg, nosebleeds) even when
these proposed criteria for desmopressin responsiveness would
not be met. This does not imply that desmopressin cannot be used
in these situations, but rather the definition would allow documentation
that a clinical response can be obtained and establish a standardized
definition for future use in surgical or emergency situations or in clinical
trials for people with VWD. Individual clinical response may also vary
and should be taken into consideration in practice. Desmopressin has
effects on coagulation beyond just elevation of VWF levels. There are
also data suggesting desmopressin responsiveness may change with
age, so repeat testing may be in order.14,15
Prophylaxis
Proposed definition
Prophylaxis in VWD is a period of at least 3 to 6 months of treatment
consisting of VWF concentrate administered at least once weekly,
or for women with HMB, use of VWF concentrate administered at
least once per menstrual cycle.
Comment
Most research studies of prophylaxis will likely require at least
6 months of therapy to establish efficacy and safety. However, in
some situations, such as children with profound epistaxis during
cold weather, a shorter duration may be appropriate; therefore, the
definition includes the option of a shorter time period. Many patients
on prophylaxis, however, will derive greater clinical benefit from
prophylaxis for .6 months.16
There are currently several different VWF concentrates available,
including plasma-derived formulations with both VWF and FVIII, as
well as recombinant VWF (which does not contain FVIII). The use of
specific products will likely depend on multiple factors and therefore
is not specified here.
This definition is consistent with that used in previous studies of
VWD prophylaxis16-18 and includes an option for a shorter time
frame in specific situations.
Major bleeding in VWD
Proposed definition
Major bleeding includes episodes requiring hospital admission,
surgical intervention, blood transfusion, hemoglobin drop of$2 g/dL,
bleeding involving critical areas (eg, intracranial, intraspinal, intra-
ocular, retroperitoneal, intra-articular, pericardial, or intramuscular
with compartment syndrome), or recurrent bleeding affecting the
ability to attend normal schooling, working, or social activity.
Comment
This definition is consistent with previously published definitions by
the International Society on Thrombosis and Haemostasis (ISTH)
for major bleeding in both nonsurgical and surgical settings.19,20
Recent definitions have been published regarding major bleed-
ing for patients on anticoagulation therapy with more specific
details in terms of cardiac bleeding.21 Similar criteria to those
proposed here have also been used in evaluation of bleeding for
anticoagulation trials.22
In the VWD literature, the definition of major bleeding includes
bleeding leading to hospital admission, treatment with VWF con-
centrate for at least 48 hours, or “life-threatening bleeding.”23 The
definition proposed here does not include use of VWF concentrate
because this should be started once any significant bleeding event
is recognized. It is anticipated that these definitions would be used
in studies of treatment of patients with an existing diagnosis of
VWD. The ISTH bleeding assessment tool is commonly used to
measure bleeding prior to diagnosis of VWD.24 The proposed
definition would be similar to a score of 4 on the ISTH bleeding




Major surgery includes surgical procedures involving cranial, spinal,
and great body cavities, joints, impacted third molar extraction, or
interventions where subject’s life is imminently at risk. In patients
with VWD, this category also includes tonsillectomy, dental extractions
with use of mandibular block or multiple extractions, liver or
kidney biopsy, gastrointestinal polypectomy, cervical cone biopsy,
or extended procedures with high risk of bleeding.
Comment
The definition has been addressed in several studies of VWF
concentrate. Windyga and colleagues used a definition similar to
that given above.25 Gill and colleagues considered major surgery to
be operations involving considerable hazard to life or limb and
included multiple tooth extractions as major surgery.26 Literature on
treatment of anticoagulated patients undergoing surgery also
provides a definition of major surgery, slightly broader in scope
with inclusion of procedures lasting.45 minutes and greater detail
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on types of surgeries considered major, including laminectomy,
prostate resection, polypectomy, variceal treatment, percutaneous
endoscopic gastrostomy placement, and multiple tooth extrac-
tions.27 Control of hemostasis is addressed in Table 1.28,29
Heavy menstrual bleeding
Proposed definition
Menstrual bleeding meeting any of the following criteria:
c Lasting $8 days
c Consistently soaks through 1 or more sanitary protections every
2 hours on multiple days
c Requires use of .1 sanitary protection item at a time
c Requires changing sanitary protection during the night
c Associated with repeat passing of blood clots
c Pictorial Blood Assessment Chart (PBAC) score .100
Comment
In clinical practice, HMB is defined as excessive menstrual loss,
which interferes with a woman’s physical, social, emotional, and/or
material quality of life.30 In terms of blood loss, HMB is defined as
a menstrual blood loss of .80 mL per period.31 This objective
assessment can only be obtained by laborious, expensive, and
inconvenient measurements involving collection of used sanitary
protections. Therefore, simple indirect methods, such as detailed
menstrual history or the use of PBAC,32 are used to provide
a semiquantitative assessment of the blood loss and its severity as
well as monitoring response to treatment. Although no consensus




Primary postpartum hemorrhage (PPH) includes blood loss$1000mL
within 24 hours of birth or any blood loss with the potential to produce
hemodynamic instability. Of note, once blood loss exceeds 500 mL in
a vaginal birth, early intervention with measures known to reduce PPH
(eg, uterotonics, tranexamic acid) should be considered.
Comment
Assessment of blood loss is essential to identify PPH and its
severity. Visual estimation often provides an underestimate of
actual blood loss especially with a blood loss of .1000 mL,33
leading to a delay in diagnosis and timely activation of PPH
protocols. Direct measurement of blood loss using graduated
containers in combination with gravimetric weight measurement of
blood on all drapes, incontinence pads, sanitary pads, and swabs,
converting 1 g to 1 mL, provides a better estimation of blood loss
with minimal resources.34 No consensus definition of PPH exists




Secondary PPH includes blood loss that is heavier than normal
lochial loss between 24 hours and 6 weeks postpartum and
c Necessitates medical review or intervention between 24 hours
and 6 weeks postpartum, or
c Lasts beyond 6 weeks after childbirth
Comment
Normal lochia is physiological vaginal bleeding postpartum. It is
typically fresh red blood with mucus in the first 3 days after
childbirth, tapering to dark red/brownish light loss by day 10 after
delivery. It can last up to 6 weeks with brownish/yellowish watery
discharge or spotting. The use of PBAC can be a useful to tool for
assessment of lochia and its duration and should be used in women
with bleeding disorders during the puerperium.35
Conclusion
It is hoped that adoption of these definitions will improve the ability
of researchers to achieve consistent endpoints in future VWD
clinical trials, ultimately enabling improved treatments for affected
patients.
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Table 1. Grading of hemostatic response for surgical procedures
Rating Hemostatic assessment Bleeding
Excellent Hemostasis achieved was as good or better
than that expected for the type of surgical
procedure performed in a hemostatically
normal subject
No different than normal
individuals
Good Hemostasis achieved was probably as good
as that expected for the type of surgical
procedure performed in a hemostatically
normal subject
Slight oozing
Moderate Hemostasis was clearly less than optimal for
the type of procedure performed but was




Poor Patient experienced uncontrolled bleeding that
was the result of inadequate therapeutic
response to the treatment used
Uncontrolled bleeding
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31. Hallberg L, Högdahl AM, Nilsson L, Rybo G. Menstrual blood loss–a
population study. Variation at different ages and attempts to define
normality. Acta Obstet Gynecol Scand. 1966;45(3):320-351.
32. Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual
blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;
97(8):734-739.
33. Stafford I, Dildy GA, Clark SL, Belfort MA. Visually estimated and
calculated blood loss in vaginal and cesarean delivery. Am J Obstet
Gynecol. 2008;199(5):519.e1-519.e7.
34. LilleyG, Burkett-St-Laurent D, Precious E, et al. Measurement of blood loss
during postpartum haemorrhage. Int J Obstet Anesth. 2015;24(1):8-14.
35. Chi C, Bapir M, Lee CA, Kadir RA. Puerperal loss (lochia) in women
with or without inherited bleeding disorders. Am J Obstet Gynecol.
2010;203(1):56.e1-56.e5.

















L user on 25 February 2021
